The present invention provides compounds of Formula I: ##STR00001## wherein the variables A, B, Ar, R.sup.1, R.sup.2, and R.sup.3 are as defined herein. The compounds of Formula (I) can function as corticotropin releasing factor (CRF) receptor antagonists and can be useful, for example, in the treatment of disorders characterized by abnormal levels of CRF such as anxiety and depression.